Pseudoprogression versus true progression in glioblastoma patients: a multiapproach literature review. Part 2 - Radiological features and metric markers.
Fiche publication
Date publication
janvier 2021
Journal
Critical reviews in oncology/hematology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine, Pr NOEL Georges, Dr SCHOTT Roland, Dr CEBULA Hélène, Dr LE FEVRE Clara
Tous les auteurs :
Le Fèvre C, Constans JM, Chambrelant I, Antoni D, Bund C, Leroy-Freschini B, Schott R, Cebula H, Noël G
Lien Pubmed
Résumé
After chemoradiotherapy for glioblastoma, pseudoprogression can occur and must be distinguished from true progression to correctly manage glioblastoma treatment and follow-up. Conventional treatment response assessment is evaluated via conventional MRI (contrast-enhanced T1-weighted and T2/FLAIR), which is unreliable. The emergence of advanced MRI techniques, MR spectroscopy, and PET tracers has improved pseudoprogression diagnostic accuracy. This review presents a literature review of the different imaging techniques and potential imaging biomarkers to differentiate pseudoprogression from true progression.
Mots clés
Diffusion MRI, Glioblastoma, MRS, PET tracers, Perfusion MRI, Progression, Pseudoprogression
Référence
Crit Rev Oncol Hematol. 2021 Jan 27;:103230